Leading Ophthalmologists Highlight the Importance of Illuvien for Chronic DME in the First US Review After the Long Awaited FDA Approval

LONDON, November 5, 2015 /PRNewswire/ --

US Ophthalmic Review, the peer-reviewed journal, has published a review highlighting the benefits of Illuvien for chronic DME

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

ABSTRACT

The antivascular endothelial growth factor (VEGF) ranibizumab (Lucentis) and aflibercept (EYLEA) and the intraocular corticosteroids dexamethasone (Ozurdex) and fluocinolone acetonide (ILUVIEN) are approved for treating diabetic macular edema (DME) in the US. Here, we review each therapy and consider the advantages of administering a corticosteroid as a slow-release implant. A suboptimal response is seen in about 50 % of DME patients treated with anti-VEGF therapy. In such patients corticosteroids are an attractive alternative. Treatment with a course of corticosteroids to indicate if a clinically significant rise in intraocular pressure may occur is required before commencing ILUVIEN. Then the physician can make a clinical decision on the treatment. ILUVIEN offers the advantage of providing 36 months of drug release from a single implant. With the availability of four drugs to treat DME, it is important to consider the optimal treatment for the individual patient.

The full peer-reviewed, open-access article is available here:

http://www.touchophthalmology.com/articles/iluvien-new-approach-treatment-diabetic-macula-edema

Note to the Editor

touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the US Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchOPHTHALMOLOGY.com

For inquires please contact:

Nicola Cartridge - Managing Editor
[email protected]
T: +44(0)207-193-3186

Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE www.touchOPHTHALMOLOGY.com